Showing results (81-90 of 132) with videos related to
Sort By:
Pageof 14
Journal of Medical Economics|December 15, 2015
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the USSumanta K Pal, Eric Jonasch, James E Signorovitch, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 5, 2008
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapyScott D Ramsey, Zhimei Liu, Rob Boer, et al.Journal of Medical Economics|November 26, 2014
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the USAllison Perrin, Steven Sherman, Sumanta Pal, et al.Clinical Genitourinary Cancer|December 29, 2015
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart ReviewsSumanta K Pal, James E Signorovitch, William M Reichmann, et al.Current Medical Research and Opinion|December 17, 2013
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record reviewMichael K Wong, Hongbo Yang, James E Signorovitch, et al.Current Medical Research and Opinion|July 2, 2014
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practicesEric Jonasch, James E Signorovitch, Peggy L Lin, et al.BMC Medical Genetics|July 18, 2020
Novel ECHS1 mutations in Leigh syndrome identified by whole-exome sequencing in five Chinese families: case reportDan Sun, Zhimei Liu, Yongchu Liu, et al.Orphanet Journal of Rare Diseases|April 11, 2025
Preliminary investigation on the economic cost of mitochondrial disease in Chinese childrenChaolong Xu, Dan Zhao, Xin Duan, et al.Clinical Genitourinary Cancer|June 12, 2012
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinomaChi-Chang Chen, Gregory P Hess, Zhimei Liu, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|March 3, 2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USASumanta K Pal, James E Signorovitch, Nanxin Li, et al.Pageof 14